Roubaud Guilhem Profile
Roubaud Guilhem

@RoubaudG

Followers
135
Following
1K
Statuses
825

Joined June 2019
Don't wanna be here? Send us removal request.
@RoubaudG
Roubaud Guilhem
6 days
RT @IcahnMountSinai: We’re proud to announce that Drs. Nina Bhardwaj (@BhardwajLab) and @MesudeBicak have been awarded the 2024–2025 Pilot…
0
4
0
@RoubaudG
Roubaud Guilhem
6 days
RT @srviswanathan: 🚨 New study! 🚨Excited to share our research on #translocationRCC #tRCC published in @NatMetabolism, in collaboration wit…
0
44
0
@RoubaudG
Roubaud Guilhem
6 days
RT @tompowles1: Bladder cancer highlights #ASCOGU25 1) outcomes of pCR patients for gem/cis/durvalumab (NIAGARA) 2) neoadjuvant gem/cis/dur…
0
28
0
@RoubaudG
Roubaud Guilhem
7 days
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial - European Journal of Cancer
0
1
2
@RoubaudG
Roubaud Guilhem
12 days
RT @DrNeilStone: None of these are cancer treatments This is dangerous misinformation If you are unfortunate enough to be diagnosed with…
0
423
0
@RoubaudG
Roubaud Guilhem
12 days
RT @jgong15: @MPishvaian @DrGallent How do we give triplet tx in the clinic? (ARPI + doce started w/in 6 weeks of #ADT in PEACE-1) @EdwinPo
0
5
0
@RoubaudG
Roubaud Guilhem
14 days
RT @EAntonarakis: Congrats to John Lozada (MD/PhD student) for deeply characterizing DLL3 expression in neuroendocrine cancers across 29 tu…
0
4
0
@RoubaudG
Roubaud Guilhem
14 days
RT @lonnibesancon: 🚨Vaccinez vos enfants contre le HPV!🚨 Bien sur, des cas pourront apparaitre lorsque les femmes de l'étude dépasseront l…
0
81
0
@RoubaudG
Roubaud Guilhem
14 days
RT @Adam_Weiner535: 🚨Not all #prostatecancer BCRs are created equally!!🚨 👉Many interesting takeaways in this Swedish population-based st…
0
16
0
@RoubaudG
Roubaud Guilhem
15 days
RT @Avokayon: La France ! 1827 - 32,6 M hab. => 7.789 magistrats 2025 -68,4 M hab. => 9.000 magistrats (théorie) Quelle autre administrati…
0
43
0
@RoubaudG
Roubaud Guilhem
16 days
RT @cancer_evolve: PROSTATE: in patients with a BRCA1/2 or PALB2 mutation receiving PARP inhibition for advanced disease, progression was a…
0
12
0
@RoubaudG
Roubaud Guilhem
18 days
RT @DavidBenjaminMD: Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma? In @EurUrolOncol, we di…
0
14
0
@RoubaudG
Roubaud Guilhem
19 days
RT @EurUrolOncol: PTEN Loss Is Associated with Adverse Outcomes in the Setting of Salvage Radiation Therapy by Emerson Lee, Lia DePaula Oli…
0
5
0
@RoubaudG
Roubaud Guilhem
20 days
RT @urotoday: Combining EZH2 and AR targeting in metastatic castration-resistant #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaa
0
9
0
@RoubaudG
Roubaud Guilhem
22 days
RT @bavilima: PEACE-3 is a Randomized multicenter Ph3 study for 1L mCRPC patients who didn’t use ARPI in mCSPC that compared the use of ADT…
0
4
0
@RoubaudG
Roubaud Guilhem
25 days
RT @DrYukselUrun: An excellent overview by @AlbigesL on systemic therapy for metastatic ccRCC, presented at the Florence Multidisciplinary…
0
4
0
@RoubaudG
Roubaud Guilhem
25 days
RT @BertrandTOMBAL: On the importance of optimal bone protection in patients receiving AR pathway inhibitors..@Silke_Gillessen Fred Saad a…
0
7
0
@RoubaudG
Roubaud Guilhem
27 days
RT @barlesi: Plus accessible que jamais, notre Institut renforce son ouverture au monde pour accueillir patients, visiteurs, partenaires… e…
0
5
0
@RoubaudG
Roubaud Guilhem
27 days
RT @foundmyfitness: Vitamin D supplementation was associated with a 40% lower risk of dementia over a decade, a relatively recent study sho…
0
1K
0